Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce. This prospective, observational, multicentric study aimed to assess the long-term effectiveness and safety of tralokinumab in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Calabrese, Elisa Cinotti, Martina D’Onghia, Alessandra Cartocci, Pietro Rubegni, François Maccari, Claire Boulard, Ziad Reguiai, Pierre-André Becherel, Caroline Jacobzone, Edouard Begon, Charlotte Fite, Beatrice Walls, Anne Laure Liegeon, Josiane Parier, Guillaume Chaby, Jean-Luc Perrot
Format: Article
Language:English
Published: Medical Journals Sweden 2025-03-01
Series:Acta Dermato-Venereologica
Subjects:
Tralokinumab
antibodies
monoclonal
clinical effectiveness
patient-relevant outcomes
atopic dermatitis
Online Access:https://medicaljournalssweden.se/actadv/article/view/42275
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://medicaljournalssweden.se/actadv/article/view/42275

Similar Items